000			01500 a2200409 4500
005			20250515111814.0
264		0	_c20080313
008			200803s 0 0 eng d
022			_a1744-7666
024	7		_a10.1517/14656566.9.4.561 _2doi
040			_aNLM _beng _cNLM
100	1		_aJoseph, Jomy
245	0	0	_aThe role of carbapenems in the treatment of severe nosocomial respiratory tract infections. _h[electronic resource]
260			_bExpert opinion on pharmacotherapy _cMar 2008
300			_a561-75 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAnti-Bacterial Agents _xadministration & dosage
650	0	4	_aCarbapenems _xadministration & dosage
650	0	4	_aCross Infection _xdrug therapy
650	0	4	_aDoripenem
650	0	4	_aDrug Administration Schedule
650	0	4	_aDrug Resistance, Multiple, Bacterial
650	0	4	_aErtapenem
650	0	4	_aHumans
650	0	4	_aImipenem _xtherapeutic use
650	0	4	_aMeropenem
650	0	4	_aPatient Selection
650	0	4	_aPneumonia, Bacterial _xdrug therapy
650	0	4	_aRespiratory Tract Infections _xdrug therapy
650	0	4	_aSeverity of Illness Index
650	0	4	_aThienamycins _xtherapeutic use
650	0	4	_aTreatment Outcome
650	0	4	_abeta-Lactams _xtherapeutic use
700	1		_aRodvold, Keith A
773	0		_tExpert opinion on pharmacotherapy _gvol. 9 _gno. 4 _gp. 561-75
856	4	0	_uhttps://doi.org/10.1517/14656566.9.4.561 _zAvailable from publisher's website
999			_c17815175 _d17815175